Shaw S, White JD. Cis-2,5-Diaminobicyclo[2.2.2]octane, a new chiral scaffold for asymmetric catalysis. Acc Chem Res. 2016;49:1825–1834.
Shaw S, Tarr JC, Pelz N, et al. Discovery of potent 2-Indole-acylsulfonamide Mcl-1 inhibitors using structure guided fragment-based methods. Cancer Res. 2016;76(14):4331.
Pelz NF, Bian Z, Zhao B, Shaw S, et al. Discovery of 2-Indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods. J Med Chem. 2016;59:2054–2066.
Burke JP, Bian Z, Shaw S. et al. Discovery of tricyclic indoles that potentially inhibit Mcl-1 using fragment based methods and structure based design. J Med Chem. 2015;58:3794–3805.
Shaw S, White JD. Regioselective and enantioselective addition of sulfur nucleophiles to acyclic α,β,γ,δ-Unsaturated dienones catalyzed by an iron(III)-salen complex. Org. Lett. 2015;17:4564–4567.
Subrata Shaw, Ph.D.
Subrata Shaw is a research scientist working under the direction of Robert Hilgraf in the Chemical Biology Program of the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. He works within the NIH-funded project “Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents” as a part of the Centers of Excellence for Translational Research (CETR), with a research goal that focuses on developing therapeutics to enhance the host autophagy pathway and autophagy-related genes (ATG genes). These targets exhibit broad protective effects against viruses, bacteria, and parasites, including West Nile virus, chikungunya virus, norovirus, Mycobacterium tuberculosis, Listeria monocytogenes, Salmonella typhimurium, and Toxoplasma gondii.
Prior to joining the Broad Institute in March 2017, Shaw participated in the 2017 Drew University Residential School on Medicinal Chemistry and Biology in Drug Discovery. He previously had completed the BRET Postdoctoral Fellowship in cancer drug discovery at Vanderbilt University Medical Center under the supervision of Stephen W. Fesik.
During this time, he designed and synthesized potent small-molecule inhibitors for Mcl-1 (myeloid cell leukemia 1), employing fragment-based methods and structure-based design. During his doctoral studies, he worked as a teaching assistant supervising and tutoring undergraduate students and spent a year as a collaborative research assistant at the Oregon Translational Research & Development Institute.
Among the honors awarded to Shaw during his academic training are the N. L. Tartar Research Fellowship, Milton Harris Scholarship, Benedict Award, Brockhouse Institute of Material Research Fellowship, National Merit Scholarship, and the Royal Society of Chemistry (London) Deccan Section Research Fellowship. He has also worked as a volunteer in several mentoring programs for undergraduate students and childhood education. He presently serves as the editor-in-chief for the World Journal of Organic Chemistry and as a reviewer for several journals including Journal of Medicinal Chemistry, Organic Letters, Chemical Scienc, and Scientific Reports.
Shaw obtained his Ph.D. under the supervision of James D. White at Oregon State University. He holds a M.Sc. in chemistry from the Indian Institute of Technology, Kanpur, India, a B.Sc. (hons) in chemistry from the University of Calcutta, and a research training certificate from Brockhouse Institute for Materials Research, McMaster University, Canada.
Contact Subrata Shaw via email at firstname.lastname@example.org.